First Time Loading...

Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 5.11 USD 6.02% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

IBRX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

ImmunityBio, Inc. is a clinical stage immunotherapy company. [ Read More ]

The intrinsic value of one IBRX stock under the Base Case scenario is 15.37 USD. Compared to the current market price of 5.11 USD, Immunitybio Inc is Undervalued by 67%.

Key Points:
IBRX Intrinsic Value
Base Case
15.37 USD
Undervaluation 67%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Immunitybio Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IBRX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Immunitybio Inc

Provide an overview of the primary business activities
of Immunitybio Inc.

What unique competitive advantages
does Immunitybio Inc hold over its rivals?

What risks and challenges
does Immunitybio Inc face in the near future?

Has there been any significant insider trading activity
in Immunitybio Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immunitybio Inc.

Provide P/S
for Immunitybio Inc.

Provide P/E
for Immunitybio Inc.

Provide P/OCF
for Immunitybio Inc.

Provide P/FCFE
for Immunitybio Inc.

Provide P/B
for Immunitybio Inc.

Provide EV/S
for Immunitybio Inc.

Provide EV/GP
for Immunitybio Inc.

Provide EV/EBITDA
for Immunitybio Inc.

Provide EV/EBIT
for Immunitybio Inc.

Provide EV/OCF
for Immunitybio Inc.

Provide EV/FCFF
for Immunitybio Inc.

Provide EV/IC
for Immunitybio Inc.

Show me price targets
for Immunitybio Inc made by professional analysts.

What are the Revenue projections
for Immunitybio Inc?

How accurate were the past Revenue estimates
for Immunitybio Inc?

What are the Net Income projections
for Immunitybio Inc?

How accurate were the past Net Income estimates
for Immunitybio Inc?

What are the EPS projections
for Immunitybio Inc?

How accurate were the past EPS estimates
for Immunitybio Inc?

What are the EBIT projections
for Immunitybio Inc?

How accurate were the past EBIT estimates
for Immunitybio Inc?

Compare the revenue forecasts
for Immunitybio Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immunitybio Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immunitybio Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immunitybio Inc compared to its peers.

Compare the P/E ratios
of Immunitybio Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Immunitybio Inc with its peers.

Analyze the financial leverage
of Immunitybio Inc compared to its main competitors.

Show all profitability ratios
for Immunitybio Inc.

Provide ROE
for Immunitybio Inc.

Provide ROA
for Immunitybio Inc.

Provide ROIC
for Immunitybio Inc.

Provide ROCE
for Immunitybio Inc.

Provide Gross Margin
for Immunitybio Inc.

Provide Operating Margin
for Immunitybio Inc.

Provide Net Margin
for Immunitybio Inc.

Provide FCF Margin
for Immunitybio Inc.

Show all solvency ratios
for Immunitybio Inc.

Provide D/E Ratio
for Immunitybio Inc.

Provide D/A Ratio
for Immunitybio Inc.

Provide Interest Coverage Ratio
for Immunitybio Inc.

Provide Altman Z-Score Ratio
for Immunitybio Inc.

Provide Quick Ratio
for Immunitybio Inc.

Provide Current Ratio
for Immunitybio Inc.

Provide Cash Ratio
for Immunitybio Inc.

What is the historical Revenue growth
over the last 5 years for Immunitybio Inc?

What is the historical Net Income growth
over the last 5 years for Immunitybio Inc?

What is the current Free Cash Flow
of Immunitybio Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Immunitybio Inc.

Financials

Balance Sheet Decomposition
Immunitybio Inc

Current Assets 294.1m
Cash & Short-Term Investments 266.5m
Receivables 3.2m
Other Current Assets 24.5m
Non-Current Assets 210.4m
Long-Term Investments 891k
PP&E 182.7m
Intangibles 17.1m
Other Non-Current Assets 9.7m
Current Liabilities 58.3m
Accounts Payable 9.2m
Accrued Liabilities 46.5m
Other Current Liabilities 2.6m
Non-Current Liabilities 1B
Long-Term Debt 837m
Other Non-Current Liabilities 196.2m
Efficiency

Earnings Waterfall
Immunitybio Inc

Revenue
622k USD
Operating Expenses
-362m USD
Operating Income
-361.4m USD
Other Expenses
-221.8m USD
Net Income
-583.2m USD

Free Cash Flow Analysis
Immunitybio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IBRX Profitability Score
Profitability Due Diligence

Immunitybio Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional ROE
Exceptional 1-Year Revenue Growth
ROIC is Increasing
32/100
Profitability
Score

Immunitybio Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

IBRX Solvency Score
Solvency Due Diligence

Immunitybio Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
36/100
Solvency
Score

Immunitybio Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IBRX Price Targets Summary
Immunitybio Inc

Wall Street analysts forecast IBRX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IBRX is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.

Lowest
Price Target
5.05 USD
1% Downside
Average
Price Target
5.1 USD
0% Downside
Highest
Price Target
5.25 USD
3% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IBRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IBRX Price
Immunitybio Inc

1M 1M
0%
6M 6M
+149%
1Y 1Y
+126%
3Y 3Y
-73%
5Y 5Y
-81%
10Y 10Y
-81%
Annual Price Range
5.11
52w Low
1.255
52w High
6.41
Price Metrics
Average Annual Return -54.28%
Standard Deviation of Annual Returns 24.93%
Max Drawdown -97%
Shares Statistics
Market Capitalization 3.4B USD
Shares Outstanding 670 331 008
Percentage of Shares Shorted 38.97%

IBRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Immunitybio Inc Logo
Immunitybio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.4B USD

Dividend Yield

0%

Description

ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2015-07-28. The firm is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its immunotherapy and cell therapy platforms include antibody cytokine fusion proteins; synthetic immunomodulators; vaccine technologies, which includes human adenovirus (hAd5) viral vector, and genetically modified off-the-shelf natural killer cells (NK cells), which activate both the innate (NK cell and macrophage) and adaptive (T cell) immune systems. Its lead cytokine fusion protein, Anktiva, is an interleukin-15 (IL-15) superagonist complex. Its clinical pipeline consists of approximately 26 actively recruiting clinical trials of which 17 are in Phase II or III development, across 13 indications in liquid and solid tumors, including bladder, pancreatic, and lung cancers, and infectious diseases, including SARS-CoV-2 and human immunodeficiency virus (HIV).

Contact

CALIFORNIA
San Diego
3530 John Hopkins Ct
+18586330300.0
https://immunitybio.com/

IPO

2015-07-28

Employees

587

Officers

Executive Chairman of the Board, Global Chief Scientific & Medical Officer
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
President, CEO & Director
Mr. Richard Gerald Adcock
CFO, Principal Financial Officer & Principal Accounting Officer
Mr. David C. Sachs
Chief Corporate Affairs Officer & Director
Dr. Barry J. Simon M.D.
Chief Operating Officer
Dr. Leonard S. Sender M.D.
Chief Technology Officer
Dr. Enrique Diloné Ph.D., RAC
Show More
General Counsel & Corporate Secretary
Mr. Jason R. Liljestrom
Chief Communications Officer & Head of Patient Advocacy
Ms. Sarah Singleton
Chief Medical Officer
Dr. Sandeep K. Reddy M.D.
Chief Science Officer of Cellular
Dr. Hans Georg Klingemann M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one IBRX stock?

The intrinsic value of one IBRX stock under the Base Case scenario is 15.37 USD.

Is IBRX stock undervalued or overvalued?

Compared to the current market price of 5.11 USD, Immunitybio Inc is Undervalued by 67%.